Qube Research & Technologies LTD Anavex Life Sciences Corp. Transaction History

Qube Research & Technologies LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$6.55 - $9.37 $1.15 Million - $1.65 Million	-176,158 Reduced 93.72%	11,796 $77,000
Q2 2023 Aug 14, 2023	BUY	$7.66 - $9.5 $1.44 Million - $1.79 Million	187,954 New	187,954 $1.53 Million
Q4 2022 Feb 14, 2023	SELL	$7.65 - $14.43 $20,425 - $38,528	-2,670 Reduced 8.36%	29,259 $270,000
Q3 2022 Nov 14, 2022	SELL	$8.9 - $12.86 $286,268 - $413,641	-32,165 Reduced 50.18%	31,929 $330,000
Q2 2022 Aug 15, 2022	BUY	$7.31 - $12.84 $468,527 - $822,966	64,094 New	64,094 $642,000
Q1 2022 May 09, 2022	SELL	$9.74 - $17.69 $192,822 - $350,208	-19,797 Closed	0 $0
Q4 2021 Feb 01, 2022	BUY	$16.88 - $23.31 $334,173 - $461,468	19,797 New	19,797 $343,000

155

27.3M

515K

838K

Ticker AVXL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,942,800
Market Cap $673M
Description
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system (CNS) diseases. Its lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer's disease; Phase III clinical trial to treat pediatric patien...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.